| scholarly article | Q13442814 |
| P50 | author | Tania Lecomte | Q55722950 |
| P2093 | author name string | Thomas Raedler | |
| Tamara Pringsheim | |||
| Kevin Jackson | |||
| Sabina Abidi | |||
| Donald Addington | |||
| Irfan Mian | |||
| Iliana Garcia-Ortega | |||
| Kim Jackson | |||
| P2860 | cites work | DSM-5 | Q3064664 |
| A systematic review of the long-term outcome of early onset schizophrenia | Q21260322 | ||
| Early interventions to prevent psychosis: systematic review and meta-analysis | Q22242061 | ||
| Early intervention in psychosis: concepts, evidence and future directions | Q24658167 | ||
| A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis | Q26748778 | ||
| Toward earlier identification and preventative intervention in schizophrenia: evidence from the London Child Health and Development Study | Q26775725 | ||
| Gone to Pot - A Review of the Association between Cannabis and Psychosis | Q26865311 | ||
| Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data | Q29616031 | ||
| Research in people with psychosis risk syndrome: a review of the current evidence and future directions | Q30475598 | ||
| Use of antipsychotic medications in pediatric populations: what do the data say? | Q30698390 | ||
| Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. | Q30773209 | ||
| The psychopathological and psychosocial outcome of early-onset schizophrenia: preliminary data of a 13-year follow-up | Q31147867 | ||
| Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review | Q33589087 | ||
| The assessment of affective disorders in children and adolescents by semistructured interview. Test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version | Q34198901 | ||
| A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia | Q34224372 | ||
| Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia | Q34377298 | ||
| AGREE II: advancing guideline development, reporting and evaluation in health care | Q34403979 | ||
| What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? | Q34442084 | ||
| Early intervention in psychosis. The critical period hypothesis | Q34474378 | ||
| EPA guidance on the early intervention in clinical high risk states of psychoses. | Q34668473 | ||
| Prescribing of antipsychotics in UK primary care: a cohort study. | Q34799674 | ||
| Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis | Q34830869 | ||
| Cannabis use, gender and age of onset of schizophrenia: data from the ÆSOP study | Q35086108 | ||
| Psychopharmacologic strategies for the treatment of aggression in juveniles. | Q35101306 | ||
| The RAISE Connection Program for Early Psychosis: Secondary Outcomes and Mediators and Moderators of Improvement | Q35554309 | ||
| Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. | Q35572650 | ||
| Quantifying clinical relevance in the treatment of schizophrenia | Q35819467 | ||
| Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. | Q55034261 | ||
| Schizophrenia with childhood and adolescent onset--a nationwide register-based study | Q71725120 | ||
| Delay in treating schizophrenia may narrow therapeutic window of opportunity | Q73737023 | ||
| Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison | Q80670929 | ||
| Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents | Q84294208 | ||
| Twenty-five year mortality of a community cohort with schizophrenia | Q36028183 | ||
| Schizophrenia and suicide: systematic review of risk factors | Q36182528 | ||
| PRN sedation-patterns of prescribing and administration in a child and adolescent mental health inpatient service. | Q36438829 | ||
| Therapeutic alliance in early schizophrenia spectrum disorders: a cross-sectional study | Q36866873 | ||
| Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study | Q37031821 | ||
| Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP) | Q37067500 | ||
| Services for people at high risk improve outcomes in patients with first episode psychosis | Q37106443 | ||
| Recommendations for pharmacological management of inpatient aggression in children and adolescents. | Q37726988 | ||
| From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics | Q37771644 | ||
| Does the therapeutic relationship predict outcomes of psychiatric treatment in patients with psychosis? A systematic review | Q37825384 | ||
| Neurobiology and phenotypic expression in early onset schizophrenia | Q37832780 | ||
| Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics | Q37887093 | ||
| Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach | Q38077898 | ||
| Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings | Q38124448 | ||
| New developments in diagnosis and treatment update: Schizophrenia/first episode psychosis in children and adolescents | Q38267730 | ||
| Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. | Q38292072 | ||
| Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends | Q38531423 | ||
| Clinical Characteristics and Predictors of Outcome of Schizophrenia-Spectrum Psychosis in Children and Adolescents: A Systematic Review | Q38823146 | ||
| Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia | Q39340879 | ||
| Guidelines for the Pharmacotherapy of Schizophrenia in Adults | Q39432209 | ||
| Psychotic-like experiences in the general community: the correlates of CIDI psychosis screen items in an Australian sample | Q39737184 | ||
| Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Children and Youth | Q40050496 | ||
| Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology | Q40625985 | ||
| Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study. | Q44937439 | ||
| Emerging psychosis in adolescents--a practical guide | Q46763147 | ||
| Agitation treatment for pediatric emergency patients | Q46793675 | ||
| Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis | Q47316102 | ||
| Canadian Guidelines for the Assessment and Diagnosis of Patients with Schizophrenia Spectrum and Other Psychotic Disorders | Q47316111 | ||
| Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study | Q47592542 | ||
| Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. | Q48286419 | ||
| Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study | Q48483242 | ||
| Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study | Q48829928 | ||
| Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. | Q50053223 | ||
| Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial. | Q50471035 | ||
| NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. | Q50573955 | ||
| A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. | Q50632560 | ||
| Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009-2012: focus on children, adolescents and prescriber specialty. | Q51134431 | ||
| Baseline profiles of adolescent vs. adult-onset first-episode psychosis in an early detection program. | Q51872372 | ||
| Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. | Q51915258 | ||
| Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. | Q51996001 | ||
| Cannabis dependence and psychotic symptoms in young people | Q52024293 | ||
| [Duration of untreated psychosis: A state-of-the-art review and critical analysis]. | Q53103445 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| psychosis | Q170082 | ||
| P304 | page(s) | 635-647 | |
| P577 | publication date | 2017-08-02 | |
| P1433 | published in | Canadian Journal of Psychiatry | Q5030253 |
| P1476 | title | Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth | |
| P478 | volume | 62 |
Search more.